September 24, 2021 06:22 AM EDTUpdated 05:37 PM

With Maverick now in Takeda's hands, James Scibetta turns the page; Roivant CMO leaves in favor of small IL-2 biotech

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Derek Graf

→ Another CEO opportunity has presented itself for James Scibetta, the chief executive of Maverick Therapeutics when Takeda ponied up $525 million in March …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With Maverick now in Takeda's hands, James Scibetta turns the page; Roivant CMO leaves in favor of small IL-2 biotech

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Derek Graf

Sign up to read this article for free.

Revolution Medicines' KRAS drug shows potential in early cut of lung cancer data

Boehringer’s updated results in HER2-mutated lung cancer impress

Exclusive: Can AI replace animal testing? A new biotech launches to find out

France stops Valneva's chikungunya vaccine rollout in over 65s after safety issue

Scholar Rock names new CEO, adds biotech veterans in C-suite rebuild

Revolutionizing obesity treatment: Could mitochondria hold the key to unlocking fat-specific weight loss?

With Mav­er­ick now in Takeda's hands, James Sci­bet­ta turns the page; Roivant CMO leaves in fa­vor of small IL-2 biotech

Copy Chief

Editor

Sign up to read this article for free.

With Maverick now in Takeda's hands, James Scibetta turns the page; Roivant CMO leaves in favor of small IL-2 biotech